Compare ADMA Biologics Inc (ADMA) vs NetApp Inc. (NTAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs NetApp Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while NetApp Inc. trades at $163.56 (market cap $32.48B). The key difference: NetApp Inc. is far larger — about 15.2× ADMA Biologics Inc's market cap, and NetApp Inc. pays a 1.25% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NTAP | |
|---|---|---|
Market Cap | $2.13B | $32.48B |
Sector | Health | Technology |
52-Week High | $20.38 | $181.08 |
52-Week Low | $7.60 | $94.11 |
Enterprise Value | $2.20B | $31.63B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NTAP trades at $165.78, up 7.53% in the last session, near its consensus price target of $167.45. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical signals from moving averages. Revenue grew to $6.57B in 2025 with an 18.43% net income margin, while cash flow turned positive at $840M. Recent news highlights AI-driven growth opportunities and strategic partnerships enhancing its data infrastructure offerings.
The outlook remains positive given AI demand tailwinds and solid execution, though valuation multiples are elevated. Key risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus leans neutral with a slight buy bias, suggesting cautious optimism for further upside if growth sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
